# A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood

> **NCT04679948** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Percoffedrinol®
- **DRUG:** Coumadin®
- **DRUG:** Antra MUPS®
- **DRUG:** Midazolam-ratiopharm®
- **DRUG:** BI 730357

## Key facts

- **NCT ID:** NCT04679948
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-21
- **Primary completion:** 2021-03-17
- **Final completion:** 2021-03-17
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04679948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04679948, "A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04679948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*